How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?
Susanna MeadeEmma RoutledgeEsha SharmaSailish HonapShuvra RaySimon H C AndersonJeremy SandersonJoel MawdsleyPeter M IrvingMark A SamaanPublished in: Frontline gastroenterology (2022)
2 or a greater than 50% reduction, as set out by STRIDE-II, is associated with reduced rates of overall treatment failure including CD-related surgery.